Chronic Lymphocytic Leukemia: Opportunity Analysis and Forecasts to 2027

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Chronic lymphocytic leukemia (CLL) is a form of cancer that originates from lymphocytes in the bone marrow and later invades the blood and/or lymphoid tissues. CLL treatment has been transformed since the novel oral targeted agents Imbruvica (ibrutinib), Zydelig (idelalisib), and Venclexta (venetoclax) were introduced to the market from 2014 onwards and challenged the prior dominance of chemoimmunotherapy regimens. During the forecast period, the global CLL market will welcome five new drugs—Calquence (acalabrutinib), zanubrutinib, umbralisib, ublituximab, and Revlimid (lenalidomide).
The CLL marketed is expected to experience modest growth in the 7MM (US, France, Germany, Italy, Spain, UK and Canada) from 2017-2027. This is driven by increasing incidence, driven primarily by aging populations, label expansions into the first-line setting for AbbVie/Roche’s Venclexta, frontline approval of the combination of AbbVie/Johnson & Johnson’s Imbruvica + Venclexta, and the increasing use of combination therapies instead of monotherapies or chemoimmunotherapy regimens. Generic and biosimilar erosion of some of the mainstays of CLL treatment is also expected during the forecast period, particularly the use of generic ibrutinib and biosimilar rituximab will lead to a decline in sales. A lack of innovative drugs in the late-stage pipeline with novel mechanisms of action means that next-generation agents are not expected to generate significant sales.
Key Questions Answered
Which pipeline agents are the most promising and expected to launch in the 7MM? What are the forecasted sales of these agents and what will be their impact in the CLL market?
What are the main unmet needs in CLL, which pipeline drugs will fulfil these needs, and to what extent?
What are the current research and development (R&D) strategies being explored and how can developers incorporate these methods into their business strategy?
Key Opinions Leaders (KOLs) insights across the 7MM, relating to the current treatment options and opinions on the late and early stage pipeline agents.


Overview of CLL, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.

Annualized CLL therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in seven geographic regions, forecast from 2017 to 2027. Hybrid forecast model: incidence & prevalence.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the CLL therapeutics market.

Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for CLL. The most promising candidates in late-stage development are profiled.

Analysis of the current and future market competition in the global CLL market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global CLL market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global CLL market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Acerta Pharma
ADC Therapeutics
Adlai Nortye Biopharma
Aptevo Therapeutics
Asana BioSciences
Biogen Idec
BioInvent International
Boehringer Ingelheim
Boston Biomedical
Bristol-Myers Squibb
Cellectar Biosciences
Centaurus Biopharma
Cyclacel Pharmaceuticals
Dynavax Technologies
Eli Lilly
Eureka Therapeutics
Gilead Sciences
Hoffmann-La Roche
Innate Pharma
Innovative Cellular Therapeutics
Johnson & Johnson
Juno Therapeutics
Karyopharm Therapeutics
Kite Pharma
LAM Therapeutics
Mei Pharma
Merck & Co.
Eureka Therapeutics
Gilead Sciences
Hoffmann-La Roche
Innate Pharma
Innovative Cellular Therapeutics
Johnson & Johnson
Juno Therapeutics
Karyopharm Therapeutics
Kite Pharma
LAM Therapeutics
Mei Pharma
Merck & Co.
Millennium Pharmaceuticals
MingSight Pharmaceuticals
Miragen Therapeutics
Molecular Templates
Neon Therapeutics
Oncternal Therapeutics
Piqur Therapeutics
Portola Pharmaceuticals
Sunesis Pharmaceuticals
Surface Oncology
TG Therapeutics
Tolero Pharmaceuticals
Trillium Therapeutics
Zhejiang DTRM Biopharma
Ziopharm Oncology

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Chronic Lymphocytic Leukemia: Executive Summary

2.1 Modest Growth in the CLL Market Expected from 2017–2027

2.2 Combinations of Targeted Drugs

2.3 Unmet Needs Exist in CLL, Particularly for Therapies of Fixed Duration as Well as More Efficacious Therapies for Patients with Adverse Prognostic Features

2.4 Commercial Opportunity for Therapies that Provide a Cure

2.5 Late-Stage Pipeline Agents to Have Low Impact on the Future CLL Treatment Landscape

2.6 What Do Physicians Think?

2.6.1 Defined Course of Treatment

2.6.2 Combination Therapies

2.6.3 Measuring Minimal Residual Disease Negativity

2.6.4 Therapies with Curative Potential

2.6.5 Chimeric Antigen Receptor-T Cell Therapy

2.6.6 PD-1/PD-L1 Checkpoint Inhibitors

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Etiology

4.1.2 Pathophysiology

4.2 Rai and Binet Staging Systems

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.4 Forecast Methodology

5.4.1 Sources Used

5.4.2 Forecast Assumptions and Methods – Population

5.4.3 Forecast Assumptions and Methods – Diagnosed Incident Cases of CLL

5.4.4 Diagnosed Incident Cases by Stage at Diagnosis (Rai Staging and Modified Rai Staging)

5.4.5 Diagnosed Incident Cases by Stage at Diagnosis (Binet Staging)

5.4.6 High-Risk Cytogenetics (11q Deletion, 13q Deletion, 17p Deletion, p53 mutation, CD38, ZAP70 and IGHV [Unmutated]) Among the Diagnosed Incident Cases of CLL

5.4.7 Forecast Assumptions and Methods – Diagnosed Prevalent Cases of CLL

5.5 Epidemiological Forecast for CLL (2017–2027)

5.5.1 Diagnosed Incident Cases of CLL

5.5.2 Age-Specific Diagnosed Incident Cases of CLL

5.5.3 Sex-Specific Diagnosed Incident Cases of CLL

5.5.4 Diagnosed Incident Cases of CLL by Rai Stage at Diagnosis

5.5.5 Diagnosed Incident Cases of CLL by Modified Rai Stage at Diagnosis

5.5.6 Diagnosed Incident Cases of CLL by Binet Stage at Diagnosis

5.5.7 Diagnosed Incident Cases of CLL by High-Risk Cytogenetics

5.5.8 Diagnosed Prevalent Cases of CLL

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of the Analysis

5.6.3 Strengths of the Analysis

6 Current Treatment Options

6.1 Overview

6.2 Treatment Algorithms

6.2.1 Young and Fit Patients (Without 17p Deletion/p53 Mutation)

6.2.2 Elderly and Fit or Young and Unfit Patients (Without 17p Deletion/p53 Mutation)

6.2.3 Elderly and Frail Patients (Without 17p Deletion/p53 Mutation)

6.2.4 Patients with High-Risk 17p Deletion and/or p53 Mutation

6.3 Marketed Therapies

6.3.1 Anti-CD20 Monoclonal Antibodies

6.3.2 Subcutaneous Rituxan

6.3.3 BCR Inhibitors

6.3.4 BCL-2 Inhibitor

6.4 Preferred Treatments Within the Seven Major Markets

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Unmet Need and Opportunity: Efficacious Therapies for High-Risk 17p Deletion Patients

7.3 Unmet Need and Opportunity: Therapies That Are of a Limited, Definite Duration of Treatment

7.4 Unmet Need and Opportunity: More Efficacious Treatment Options in First-Line Therapy for Elderly and Frail, or Young and Fit Patients

7.5 Unmet Need and Opportunity: Prognostic Markers That Determine the Optimal Treatment Strategy

7.6 Unmet Need and Opportunity: Identification of Patients Who Could Benefit from Early Treatment

8 R&D Strategies

8.1 Overview

8.1.1 Targeting the High-Risk 17p Deletion Population

8.1.2 Targeting Other B-Cell Receptor Proteins

8.1.3 Combination Therapies

8.2 Clinical Trials Design

8.2.1 Ongoing Late-Stage Clinical Trials of Marketed and Pipeline Drugs

8.2.2 Evaluating CLL Clinical Trial Endpoints

8.2.3 Selecting Suitable Comparator Arms

9 Pipeline Assessment

9.1 Overview

9.1.1 Umbralisib and Ublituximab

9.1.2 Calquence and Zanubrutinib

9.1.3 Revlimid

9.2 Innovative Early-Stage Approaches

9.2.1 PD-1/PD-L1 Checkpoint Inhibitors

9.2.2 Chimeric Antigen Receptor T Cell Therapy

9.2.3 Other Innovative Approaches

9.3 Summary of Products in Development for CLL

10 Pipeline Valuation Analysis

10.1 Clinical Benchmark of Key Pipeline Drugs

10.2 Commercial Benchmark of Key Pipeline Drugs

10.3 Competitive Assessment

10.4 Top-Line 10-Year Forecast

10.4.1 US

10.4.2 5EU

10.4.3 Canada

11 Appendix

11.1 Bibliography

11.2 Abbreviations

11.3 Methodology

11.3.1 Forecasting Methodology

11.3.2 Diagnosed Patients

11.3.3 Percent Drug-Treated Patients

11.3.4 Drugs Included in Each Therapeutic Class

11.3.5 Launch and Patent Expiry Dates

11.3.6 General Pricing Assumptions

11.3.7 Individual Drug Assumptions

11.3.8 Generic/Biosimilar Erosion

11.3.9 Pricing of Pipeline Agents

11.4 Primary Research – Key Opinion Leaders Interviewed for This Report

11.4.1 KOLs

11.5 Primary Research – Prescriber Survey

11.6 About the Authors

11.6.1 Analyst

11.6.2 Managing Analyst

11.6.3 Therapy Area Directors

11.6.4 Epidemiologist

11.6.5 Epidemiologist Reviewers

11.6.6 Global Director of Therapy Analysis and Epidemiology

11.6.7 Global Head and EVP of Healthcare Operations and Strategy

11.7 About GlobalData

11.8 Contact Us

11.9 Disclaimer

Frequently asked questions

Chronic Lymphocytic Leukemia: Opportunity Analysis and Forecasts to 2027 thematic reports
Currency USD

Can be used by individual purchaser only


Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Chronic Lymphocytic Leukemia: Opportunity Analysis and Forecasts to 2027 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS

Related reports

View more Oncology reports
Immuno-oncology in pharma: neoepitope prediction
$250 | December 2023
Innovation in pharma: transdermal drug delivery
$250 | November 2023
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Chronic Lymphocytic Leukemia: Opportunity Analysis and Forecasts to 2027 in real time.

  • Access a live Chronic Lymphocytic Leukemia: Opportunity Analysis and Forecasts to 2027 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.